Use of tiamulin for preparing a drug for use as a cancer multidrug resistance reversion agent

摘要

The use of the antibiotic tiamulin for inducing drug-sensitivity in chemotherapy-resistant human or animal tumour cells as soon as the tumour appears or during tumour development and/or cancer treatment, with a view to preparing a drug for treating malignant blood diseases and solid cancerous tumours in mammals, is disclosed. The cytotoxic activity caused by increased intracellular cancer drug retention may be studied by producing highly resistant tumour lines, i.e. mouse lymphoid leukaemia line P388 resistant to 25 mu g/ml of adriamycin, rat hepatocellular carcinoma line AS30-D resistant to 5 and 10 mu g/ml of colchicine, and human lymphoblastic leukaemia line CEM resistant to 0.45, 3.6 and 5 mu g/ml of vinblastine.